Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria Cutanea tarda

Archives of Dermatology

Volumn 139, Issue 3, 2003, Pages 309-313

  Stölzel, Ulrich ^a,e   Köstler, Erich ^b   Schuppan, Detlef ^c   Richter, Matthias ^a   Wollina, Uwe ^b   Doss, Manfred O ^d   Wittekind, Christian ^e   Tannapfel, Andrea ^e  

^a KLINIKUM CHEMNITZ   (Germany)

^b ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FERRITIN; HFE PROTEIN; IRON; LIVER ENZYME; PORPHYRIN; TRANSFERRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; GENETIC ASSOCIATION; GERMANY; HEMOCHROMATOSIS; HETEROZYGOSITY; HFE GENE; HOMOZYGOSITY; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; CHLOROQUINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRITINS; GENOTYPE; GERMANY; HEMOCHROMATOSIS; HUMANS; IRON; LIVER; LIVER FUNCTION TESTS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PORPHYRIA CUTANEA TARDA; PORPHYRINS; RETROSPECTIVE STUDIES; TRANSFERRIN;

EID: 0037341145     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.3.309     Document Type: Article

References (33)

1. Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest. 1976;58:1089-1097.
2. Felsher BF, Norris ME, Shih JC. Red-cell uroporphyrinogen decarboxylase activity in porphyria cutanea tarda and in other forms of porphyria. N Engl J Med. 1978;299:1095-2008.
3. De Verneull H, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea: two different diseases. Hum Genet. 1978;44:145-151.
4. Doss M, von Tiepermann R, Look D, et al. Hereditary and non-hereditary form of chronic hepatic porphyria: different behaviour of uroporphyrinogen decarboxylase in liver and erythrocytes. Klin Wochenschr. 1980;58:1347-1356.
5. Elder GH. Porphyria cutanea tarda. Semin Liver Dis. 1998;18:67-75.
6. Francis J, Smith A. Oxidation of uroporphyrinogens by hydroxyl radicals: evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase. FEBS Lett. 1988;233:311-314.
7. Kappas A, Sassa S, Galbraith RA, Nordman Y. The porphyrias. In: Sciver CR, Beaude AL, Sly WS, Valle D, eds. The Molecular and Metabolic Basis or Inherited Disease. 7th ed. New York, NY: McGraw-Hill Co; 1995:2103-2160.
8. Sixel-Dietrich F, Doss M. Hereditary uroporphyrinogen-decarboxylase deficiency predisposing porphyria cutanea tarda (chronic hepatic porphyria) in females after oral contraceptive medication. Arch Dermatol Res. 1985;278:13-16.
9. Doss M. Hepatic porphyrias: pathobiochemical, diagnostic, and therapeutic implications. In: Popper H, Schaffner F, eds. Progress in Liver Disease. Vol 7. New York, NY: Grune & Stratton; 1982:573-597.
10. Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology. 1992;16:1322-1326.
11. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
12. Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 1997;349:321-323.
13. Santos M, Clevers HC, Marx JJ. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med. 1997;336:1327-1328.
14. D'Amato M, Macri A, Griso D, et al. Are His63Asp or Cys282Tyr HFE mutations associated with porphyria cutanea tarda? data of patients from central and southern Italy. J Invest Dermatol. 1998;111:1241-1242.
15. Salamanca RE, Morales P, Castro MJ, et al. The most frequent HFE allele linked to porphyria cutanea tarda in Mediterraneans is His63Asp. Hepatology. 1999;30:819-820.
16. Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol. 1998;26:404-409.
17. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 1998;27:1661-1669.
18. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95:1565-1571.
19. Sampietro M, Piperno A, Lupica L, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 1996;27:181-184.
20. Furuyama K, Kondo M, Hirata K, et al. Extremely rare association of HFE mutations with porphyria cutanea tarda in Japanese patients. Hepatology. 1999;30:1532-1533.
21. Ivanova A, von Ahsen N, Adjarov D, et al. C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology. 1999;30:1531-1532.
22. Kordac V, Semradova M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol. 1974;90:95-100.
23. Köstler E, Pollack P, Seebacher C, et al. Iron metabolism and chloroquine phosphate therapy in porphyria cutanea tarda. Z Hautkr. 1990;65:1030-1032.
24. Valls V, Ena J, Enriquez-De-Salamanca R. Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci. 1994;7:169-175.
25. Stölzel U, Köstler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria in cutanea tarda in Germany. Hepatology. 1995;21:1500-1503.
26. Doss M. The quantitative separation of porphyrins and protohaemin as methyl esters by thin-layer chromatography. J Chromatogr. 1967;30:265-269.
27. Tannapfel A, Stölzel U, Köstler E, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch. 2001;439:1-5.
28. Legssyer R, Ward RJ, Crichton RR, et al. Effect of chronic chloroquine administration on iron loading in the liver and reticuloendothelial system and on oxidative responses by the alveolar macrophages. Biochem Pharmacol. 1999;57:907-911.
29. Lester S, Bardy P, McCluskey J. HFE genotypes and haemochromatosis: quantifying the risks of disease. Tissue Antigens. 1999;54:282-284.
30. Mura C, Le Gac G, Raguenes D, et al. Relation between HFE mutations and mild iron-overload expression. Mol Genet Metab. 2000;69:295-301.
31. Cassanelli S, Pignatti E, Montosi G, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol. 2001;34:523-528.
32. Sinclair PR, Gorman N, Walton HS, et al. Uroporphyria in Hfe mutant mice given 5-aminolevulinate: a new model of Fe-mediated porphyria cutanea tarda. Hepatology. 2001;33:406-412.
33. Doss MD, Frank M, Braun-Falco D. Porphyria cutanea tarda: erythrocyte uroporphyrinogen decarboxylase activity in 471 consecutive patients. Curr Probl Dermatol. 1991;20:97-105.